Freddy A. Jimenez
Known title: SVP & GENERAL COUNSELCIK: 0001838114
Associated companies
Transaction History
| CLDX | ▼ Sell | Open Market | 4,166 | $121K | 12/4/2025 | View on chart |
| CLDX | ▼ Sell | Open Market | 341 | $8K | 8/13/2025 | View on chart |
| CLDX | ▼ Sell | Open Market | 430 | $11K | 8/13/2025 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 9,540 | $99K | 6/5/2024 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 8,006 | $83K | 6/3/2024 | View on chart |
| CLDX | ▼ Sell | Open Market | 8,006 | $269K | 6/3/2024 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 4,166 | $38K | 2/13/2024 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 20,000 | $56K | 2/13/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 24, 2026
Celldex shares dip after positive Phase 3 barzolvolimab results
Celldex reported that its drug barzolvolimab met endpoints in Phase 3 trials for chronic spontaneous urticaria, showing durable responses. Despite these positive results, the stock fell 11%, with some analysts noting that safety concerns appear misplaced. Major firms like Morgan Stanley and Leerink Partners recently raised their price targets, while the company continues to manage a high cash burn rate.
Celldex shares dip after positive Phase 3 barzolvolimab results. Celldex reported that its drug barzolvolimab met endpoints in Phase 3 trials for chronic spontaneous urticaria, showing durable responses. Despite these positive results, the stock fell 11%, with some analysts noting that safety concerns appear misplaced. Major firms like Morgan Stanley and Leerink Partners recently raised their price targets, while the company continues to manage a high cash burn rate.